What Happened

Xenetic Biosciences (Nasdaq: XBIO) and Santersus AG have entered into a definitive all-stock share exchange agreement. Under the terms, Xenetic will issue new shares to acquire all outstanding capital of Santersus, with Santersus equity holders receiving approximately 85% of the combined company on a fully diluted basis. The merged entity will be renamed Santersus Bio, Inc. and trade on Nasdaq under the ticker SNTS. The transaction has been unanimously approved by both boards and is expected to close in Q4 2026, pending Xenetic stockholder approval, Nasdaq listing approval, and effectiveness of a Form S-1 resale registration statement.

Who Is Affected

Employees, shareholders, and clinical trial partners of both Xenetic and Santersus are directly impacted. Santersus CEO James Ladtkow is expected to lead the combined company. The deal also affects vendors and service providers supporting the four clinical programs now under one corporate roof—including the NucleoCapture apheresis programs in sepsis and SLE and Xenetic’s DNase platform in high-risk large B-cell lymphoma.

Market Impact

The acquisition consolidates two complementary NET-targeting platforms, creating a combined pipeline with both enzymatic (DNase) and physical removal (apheresis) approaches. Key market implications include:

• Two Santersus programs hold FDA Breakthrough Device Designation, which may accelerate regulatory pathways and increase demand for quality system and regulatory compliance tools.
• Xenetic’s DNase platform, currently in a Phase Ib investigator-initiated study with CAR-T therapy, adds a clinical-stage oncology asset to the portfolio.
• All-stock structure with no cash consideration may limit near-term financial strain but puts pressure on integration efficiency.

What to Watch

Close of the transaction in Q4 2026 remains contingent on stockholder and regulatory approvals. Monitor integration of clinical operations, especially unified management of the pivotal sepsis study and the planned pivotal SLE study. The 180-day lock-up agreements for key shareholders may limit stock volatility but could also signal long-term commitment. SDRs should watch for announcements of new vendor contracts, especially in regulatory submission support and clinical data management, as the combined company scales.

Related coverage

• Telix Acquires ITM in $1.65B Radiopharmaceutical Deal
• Fortrea boosts early-phase CRO platform with $45M acquisition of Worldwide division
• Lilly to acquire Merida Biosciences for up to $2.875B
• Teva named stalking horse bidder for bankrupt BioXcel's neuroscience assets